Evaluation of prognostic factors for advanced ovarian cancer treatment with an emphasis on optimal primary cytoreduction

被引:0
作者
Vrhkar, Natasa [1 ]
Vakselj, Ales [1 ]
Verdenik, Ivan [1 ]
Smrkolj, Spela [1 ]
Barbic, Matija [1 ]
Cvjeticanin, Branko [1 ]
Meglic, Leon [1 ]
Kobal, Borut [1 ]
机构
[1] Univ Klin Ctr Ljubljana, Ginekol Klin, Klin Oddelek Ginekol, Ljubljana 1000, Slovenia
来源
ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL | 2012年 / 81卷 / 7-8期
关键词
ovarian cancer; prognostic factors; cytoreduction; residual tumour; GYNECOLOGIC-ONCOLOGY-GROUP; SURVIVAL; SURGERY; CARCINOMA; IMPACT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Initial surgical debulking followed by a systemic chemotherapy is the standard treatment sequence for advanced ovarian cancer (AOC) treatment. The purpose of this article is to evaluate prognostic factors that impact the success of AOC treatment. Methods: All patients with AOC (FIGO stage III and IV) who were surgically treated at the Division of Gynaecology, University Medical Centre of Ljubljana, in the period from 2003 to 2008 and further received cytotoxic chemotherapy at the Institute of Oncology in Ljubljana were included in this retrospective study. Women with advanced borderline ovarian cancer and patients who initially received neoadjuvant chemotherapy and those whose adjuvant chemotherapy was not platinum-based were excluded from the analysis. Results: A total of 159 women were enrolled in the study, while data were analyzed for 116 patients. Their median age was 59 years (23-80 years) and did not have a significant influence on the treatment outcome. Clear-cell histological type of AOC was an important risk factor for a disease-free interval (DFI) (HR = 2.41, CI 95 % 0.9-5.9; p = 0.08) and overall survival (OS) (HR 4.045; 95.0% CI 1.5-10.6; p = 0.003). Post-operative residual tumour larger than 2 cm represented a statistically independent risk factor for poor OS. Residual tumour in the upper abdomen did not represent a statistically significant risk factor either for DFI (HR = 1.93; CI 95 % 0.9-4.06; p = 0.08) or for OS (HR = 1.47; 95.0 % CI 0.5-3.8; p = 0.491). Median follow up time was 29.5 months, median DFI 18 months (95 % CI 16-20) and median OS 32 months (95 % CI 22-42). 74 (63.8 %) patients died. Conclusion: Clear-cell histological type of AOC and residual tumour larger than 2 cm are the most important risk factors for early progress of the disease and poor OS. Hence improvement of surgical treatment is crucial for better treatment outcomes for patients with AOC. The latter can be achieved by an interdisciplinary surgical approach.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 50 条
  • [41] The Influence of "Omental Cake" Presence on the Completeness of Cytoreduction in Advanced-stage Ovarian Cancer
    Bacalbasa, Nicolae
    Diaconu, Camelia
    Iliescu, Laura
    Savu, Cornel
    Bratu, Ovidiu Gabriel
    Bolca, Ciprian
    Cretoiu, Dragos
    Filipescu, Alexandru
    Dima, Simona
    Balalau, Cristian
    Balescu, Irina
    IN VIVO, 2020, 34 (04): : 2187 - 2191
  • [42] Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer
    Santoiemma, Phillip P.
    Reyes, Carolina
    Wang, Li-Ping
    McLane, Mike W.
    Feldman, Michael D.
    Tanyi, Janos L.
    Powell, Daniel J., Jr.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 120 - 127
  • [43] Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients
    Quan, Chenlian
    Chen, Xiaojun
    Wen, Hao
    Wu, Xiaohua
    Li, Jin
    BMC CANCER, 2024, 24 (01)
  • [44] Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature
    Papadia, Andrea
    Morotti, Matteo
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 287 (04) : 733 - 741
  • [45] Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study
    Eskander, Ramez N.
    Kauderer, James
    Tewari, Krishnansu S.
    Mannel, Robert S.
    Bristow, Robert E.
    O'Malley, David M.
    Rubin, Stephen C.
    Glaser, Gretchen E.
    Hamilton, Chad A.
    Fujiwara, Keiichi
    Huh, Warner K.
    Ueland, Frederick
    Stephan, Jean-Marie
    Burger, Robert A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (03) : 525 - 530
  • [46] The "Definitive" Trial of Surgical Cytoreduction in Advanced-Stage Ovarian Cancer
    Naik, Raj
    Spirtos, Nick
    Pomel, Christophe
    Bristow, Rob
    Chi, Dennis
    Vergote, Ignace
    Donovan, Jenny
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (04) : 588 - 591
  • [47] Role of aggressive surgical cytoreduction in advanced ovarian cancer
    Chang, Suk-Joon
    Bristow, Robert E.
    Chi, Dennis S.
    Cliby, William A.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 26 (04) : 336 - 342
  • [48] Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer
    Ataseven, Beyhan
    Grimm, Christoph
    Harter, Philipp
    Prader, Sonia
    Traut, Alexander
    Heitz, Florian
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 435 - 440
  • [49] Multimodal Treatment of Primary Advanced Ovarian Cancer
    Friedrich, Michael
    Friedrich, Dominique
    Kraft, Clayton
    Rogmans, Christoph
    ANTICANCER RESEARCH, 2021, 41 (07) : 3253 - 3260
  • [50] Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: Results of a retrospective study
    Spiliotis, John
    Iavazzo, Christos
    Fotiou, Alexandros
    Kopanakis, Nikolaos
    Terra, Alexios
    Efstathiou, Elias
    Margari, Charalambia
    Tsiatas, Marinos
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (02) : 630 - 637